Abstract
Excessive proliferation, impaired apoptotic clearance, and extracellular matrix (ECM) production are pathological features of fibroblast activation that together result in scar tissue formation in pulmonary fibrosis. This study identifies the previously unrecognized role for the WT1-MYCN-PLK1 axis in promoting fibroblast activation and highlights the therapeutic potential of PLK1 inhibition with volasertib as an antifibrotic strategy.
Funding Information
  • HHS | NIH | National Heart, Lung, and Blood Institute (1R01 HL134801)
  • HHS | NIH | National Heart, Lung, and Blood Institute (1R01 HL157176)

This publication has 58 references indexed in Scilit: